Pfizer drug delivers breakthrough in late-stage blood cancer trial

Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis

Lilly buys Ajax Therapeutics for up to $2.3 billion to target rare blood cancers

Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026

Eli Lilly posts strong Phase 3 win for Jaypirca combo in blood cancer trial

Benefits were consistent across all key subgroups, including patients previously treated with covalent BTK inhibitors

Shilpa Medicare & mAbTree Biologics win FDA nod for rare blood cancer therapy

The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options

Cellenkos scores FDA orphan drug designation for CK0804 in rare blood cancer

Receiving Orphan Drug Designation is an important milestone in the clinical development of CK0804 for myelofibrosis

CARsgen submits INDs for next-gen CAR-T therapy targeting hard-to-treat blood cancers

The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively

Imugene reports strong early results for Azer-cel in aggressive blood cancer trial

Data deluge at ASH: Bristol Myers Squibb showcases breakthroughs across blood cancers

Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM

AbbVie seeks FDA approval for Pivekimab Sunirine to treat rare, aggressive blood cancer

BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma

Lilly posts explosive Q1 2026 results

Lifts full-year outlook as obesity drug boom accelerates